Charles River, BioMotiv Enter Partnership
News Apr 15, 2016
Through this partnership, Charles River will provide discovery and preclinical development services that will enable BioMotiv to advance discoveries sourced from academic research and non-governmental organizations into novel medicines.
Charles River has committed to invest up to $10 million in BioMotiv. Through the agreement, Charles River will be the preferred drug discovery and preclinical development partner for BioMotiv’s portfolio of technologies and companies. As part of this new relationship, Professor Julie Frearson, Executive Director of Scientific Alliances for Charles River, will be joining BioMotiv’s Advisory Board.
“We look forward to our partnership with BioMotiv, and the opportunity to contribute to its mission of accelerating academic discoveries into novel therapeutics,” said Professor Frearson. “Charles River is uniquely positioned to support all stages of drug discovery and preclinical development, and using our deep industry knowledge and operational excellence, we can accelerate and optimize BioMotiv’s objective to develop innovative therapies.”
Launched in 2012, BioMotiv is the for-profit component of The Harrington Project, a $250 million initiative with an aim of identifying, funding, and rapidly advancing the development of medical discoveries from innovative physician-scientists throughout the United States and United Kingdom.
“Charles River Laboratories’ ability to support the drug research process from discovery through safety testing is unmatched in the industry,” said Baiju R. Shah, Chief Executive Officer of BioMotiv. “Access to Charles River’s extensive portfolio of services offers distinct scientific and operational advantages, which we believe will significantly accelerate the development of breakthrough medicines.”
Tiny Kidneys: Building Better Models to Test DrugsNews
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.READ MORE
Could Alzheimer's Drug Repair Brain Damage After Alcohol Binges?News
A drug used to slow cognitive decline in Alzheimer's disease could offer clues on how drugs might one day be able to reverse brain changes that affect learning and memory in teens and young adults who binge drink.READ MORE
Absolute Antibody and Kerafast Merge Increasing Access to Unique Reagents and Recombinant Antibody TechnologyNews
Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.READ MORE